Enzymatic Production Of A Protein Or Polypeptide (e.g., Enzymatic Hydrolysis, Etc.) Patents (Class 435/68.1)
-
Patent number: 10851174Abstract: A chemoenzymatic method for the preparation of a core-fucoslyated glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of an endoglycosidase (ENGase) selected from Endo;F1, Endo-F2, Endo-F3, Endo-D and related glycosynthase mutants to transfer the oligosaccharide moiety to the acceptor and yield the structure defined core-fucosylated glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of fucosylated glycoprotein or fucosylated glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody to include a predetermined sugar chain to replace a heterogeneous sugar chain, are also described.Type: GrantFiled: March 5, 2012Date of Patent: December 1, 2020Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Lai-Xi Wang, Wei Huang, John Giddens
-
Patent number: 10829795Abstract: Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.Type: GrantFiled: July 14, 2017Date of Patent: November 10, 2020Assignees: Northwestern University, Cornell UniversityInventors: Michael Christopher Jewett, Jessica Carol Stark, Matthew P. DeLisa, Thapakorn Jaroentomeechai
-
Patent number: 10801052Abstract: The present invention relates to cofactor regeneration systems, components and uses thereof and methods for generating and regenerating cofactors. The cofactor regeneration system comprises a first electron transfer component selected from a polypeptide comprising a NADH:acceptor oxido-reductase or NADPH:acceptor oxido-reductase, a second electron transfer component selected from a hydrogenase moiety and/or non-biological nanoparticles and an electronically conducting surface. The first and second electron transfer components are immobilised on the electrically conducting surface, and the first and second electron transfer components do not occur together in nature as an enzyme complex.Type: GrantFiled: October 3, 2012Date of Patent: October 13, 2020Assignees: OXFORD UNIVERSITY INNOVATION LIMITED, HUMBOLDT-UNIVERSITAT ZU BERLINInventors: Kylie Vincent, Lars Lauterbach, Oliver Lenz
-
Patent number: 10798963Abstract: A process for preparing a milk protein hydrolysate comprising hydrolysing a milk-based proteinaceous material with a microbial alkaline serine protease in combination with bromelain, a protease from Aspergillus and a protease from Bacillus.Type: GrantFiled: March 21, 2016Date of Patent: October 13, 2020Assignee: Societe des Produits Nestle S.A.Inventors: Francoise Maynard, Delphine Salvatore, Anne Thevenier
-
Patent number: 10723760Abstract: A method for producing a site-specifically modified protein based on new carbon-carbon bond formation is disclosed, including the following three steps (marking, activation, and coupling steps): (a) marking of the modification site by incorporating a specific amino acid into a selected position of a target protein; (b) activation of the marked site; and (c) coupling of various post-translational modification (PTM) moieties or other chemical groups onto the activated site to obtain a site-specifically modified protein. The method for producing a site-specifically modified protein can incorporate desired diverse chemical groups including post-translational modification (PTM) moieties into a designated site in a target protein through a new carbon-carbon bond. Furthermore, the modified protein having a site-specific PTM exhibits the same chemical and functional properties as that of a target protein present in cells.Type: GrantFiled: August 31, 2017Date of Patent: July 28, 2020Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Hee-Sung Park, Hee-Yoon Lee, Aerin Yang, Sura Ha
-
Patent number: 10683523Abstract: The present invention describes a process for in situ generation of stable GOS in different dairy products by the use of a transgalactosylating ?-galactosidase.Type: GrantFiled: December 11, 2014Date of Patent: June 16, 2020Assignee: DuPont Nutrition Biosciences ApSInventors: Morten Krog Larsen, Jacob Flyvholm Cramer, Thomas Eisele
-
Patent number: 10676499Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.Type: GrantFiled: December 16, 2015Date of Patent: June 9, 2020Assignee: NOVARTIS AGInventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Williams, Jun Yuan, Frederic Zecri
-
Patent number: 10662457Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: GrantFiled: February 16, 2018Date of Patent: May 26, 2020Assignee: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Patent number: 10640546Abstract: In some aspects, the invention relates to an insulin derivative, comprising a cyclic amino acid at position B28 or B29, wherein the cyclic amino acid is not L-proline. In some aspects, the invention relates to a method of making said insulin derivative. In some aspects, the invention relates to a pharmaceutical composition comprising said insulin derivative. In some aspects the invention relates to a method of treating a disease or condition in a subject comprising administering to the subject a composition comprising said insulin derivative.Type: GrantFiled: June 10, 2015Date of Patent: May 5, 2020Assignee: California Institute of TechnologyInventors: David A. Tirrell, Seth Lieblich, Katharine Y. Fang, Howard C. Zisser
-
Patent number: 10619177Abstract: The present invention relates to a method of producing a protein hydrolysate comprising a step of enzymatic protein hydrolysis performed at high temperature.Type: GrantFiled: December 1, 2015Date of Patent: April 14, 2020Assignee: Novozymes A/SInventor: Gitte Budolfsen Lynglev
-
Patent number: 10603407Abstract: The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.Type: GrantFiled: December 22, 2016Date of Patent: March 31, 2020Assignee: Warsaw Orthopedic, Inc.Inventors: Abdulhafez A. Selim, Lawrence A. Shimp, Hsiu Ying Sherry Wang
-
Patent number: 10519180Abstract: Biomass feedstocks (e.g., plant biomass, animal biomass, and municipal waste biomass) are processed to produce useful products, such as fuels. For example, systems are described that can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy materials, to produce a product or intermediate, e.g., energy, a food, a fuel, or a material.Type: GrantFiled: June 1, 2018Date of Patent: December 31, 2019Assignee: Xyleco, Inc.Inventors: Marshall Medoff, Thomas Craig Masterman
-
Patent number: 10479817Abstract: An approach to synthesizing and assembling nanoparticles into discrete, size-tunable, pre-designed architectures is realized in a single synthetic/process step.Type: GrantFiled: November 3, 2015Date of Patent: November 19, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Nathaniel L. Rosi, Chun-Long Chen
-
Patent number: 10465190Abstract: The present disclosure provides, in some aspects, in vitro transcription systems (including, for example, nucleic acid constructs and polymerases), the use of which increases transcription efficiency while reducing the amount of truncated single-stranded ribonucleic acid transcript produced during an in vitro transcription reaction.Type: GrantFiled: December 21, 2016Date of Patent: November 5, 2019Assignee: ModernaTX, Inc.Inventors: Jesse Chen, Athanasios Dousis
-
Patent number: 10414795Abstract: A method of preparing collagen active peptides with antiproliferative activity against cancer cells. The collagen active peptides are obtained by hydrolysis of papain and trypsin and a specific purifying process. The collagen active peptides have antiproliferative activity against cancer cells, such as ovarian carcinoma cells including SKOV3, OVCAR3, 436 and SRO82 and the prostate cancer cells including PC3, LnCAPC1, and LnCAPC2.Type: GrantFiled: March 15, 2017Date of Patent: September 17, 2019Assignees: TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMY OF SCIENCES, BAOTOU DONGBAO BIO TECH CO LTD.Inventors: Yanchuan Guo, Bing Zhang, Fang Liu, Furong Wang, Eric Hanxiang Sun, Jianing Wang
-
Patent number: 10413634Abstract: The present application relates to use of transglutaminases to treat various products, including medical devices such as tissue grafts, tissue matrices or other tissue-derived materials, and synthetics. The transglutaminases can be applied to the medical devices to provide advantages such as adhesion resistance or abrasion resistance.Type: GrantFiled: January 29, 2018Date of Patent: September 17, 2019Assignee: LifeCell CorporationInventors: Yi Chen, Sean Collins, Li Ting Huang, Eric Stec, Hui Xu
-
Patent number: 10400042Abstract: A method for conversion of an N-terminal glutamine and/or glutamic acid residue of a protein to pyro-glutamic acid within a purification process.Type: GrantFiled: April 3, 2014Date of Patent: September 3, 2019Assignee: MABXIENCE RESEARCH, S.L.Inventors: Marie Rose Van Schravendijk, Stephen Waugh, Barbara Thorne
-
Patent number: 10377825Abstract: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.Type: GrantFiled: December 14, 2017Date of Patent: August 13, 2019Assignee: Genentech, Inc.Inventors: Mary Mathieu, Mark Dennis
-
Patent number: 10377699Abstract: A method for the synthesis of daptomycin or a daptomycin analog is carried out on a resin to form a linear precursor followed by a serine ligation macrocyclization in solution. Daptomycin analogs can differ from daptomycin by substitution of amino acids residues and/or deletion or addition of amino acid residues. Daptomycin analogs can include a different fatty acid in the side arm of the daptomycin analog.Type: GrantFiled: November 6, 2013Date of Patent: August 13, 2019Assignee: The University of Hong KongInventors: Xuechen Li, Hiu Yung Lam
-
Patent number: 10358470Abstract: The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon ? activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon ? activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments.Type: GrantFiled: September 28, 2012Date of Patent: July 23, 2019Assignee: GLYTECH, INC.Inventors: Izumi Sakamoto, Kazuhiro Fukae, Katsunari Tezuka, Keisuke Tazuru, Masatoshi Maeda, Yasuhiro Kajihara, Takashi Tsuji
-
Patent number: 10308716Abstract: The invention relates to a method for producing polyclonal antibodies against an antigenic target protein which comprises inducing an immune response in a host by applying an immunogenic composition comprising membrane vesicles incorporating said antigenic target protein to said host and obtaining antibodies against said target protein from the host's serum.Type: GrantFiled: September 24, 2014Date of Patent: June 4, 2019Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V.Inventors: Marlitt Stech, Katja Hanack, Katrin Messerschmidt, Stefan Kubick
-
Patent number: 10278047Abstract: In one embodiment a method for providing presence information in a smart environment is implemented on a personal computing device associated with a user and includes: broadcasting a presence indicator signal in the smart environment, where the presence indicator signal indicates presence of the user in the smart environment, and the personal computing device is not provided by an operator of the smart environment.Type: GrantFiled: October 31, 2017Date of Patent: April 30, 2019Assignee: Cisco Technology, Inc.Inventors: David C. White, Jr., Magnus Mortensen, Jay Kemper Johnston, Rama Darbha
-
Patent number: 10259856Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.Type: GrantFiled: April 14, 2015Date of Patent: April 16, 2019Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
-
Patent number: 10259909Abstract: The present invention discloses a method for preparing glatiramer acetate, comprising: (1) dissolving L-alanine NCA, L-tyrosine NCA, L-glutamic acid-?-benzyl ester NCA, and L-?-trifluoroacetyl-lysine NCA in 1,4-dioxane as solvent, stirring until a clarified solution is formed; (2) adding diethylamine for catalysis, stirring at 20-25° C., then slowly pouring the reaction solution into water, collecting the produced white product; (3) adding the obtained product to a solution of hydrobromic acid in acetic acid, stirring at 23.0-25.0° C., pouring the reaction solution into purified water for quenching and stirring, subjecting the mixture to suction filtration to obtain a yellow solid, after repeating 3-5 times, subjecting the solid to blast drying to remove the moisture therein; and (4) dissolving the solid obtained in step (3) in a 1M piperidine aqueous solution at room temperature and stirring, subjecting the obtained solution to dialysis, adding glacial acetic acid to adjust the pH to 5.5-7.Type: GrantFiled: November 26, 2015Date of Patent: April 16, 2019Assignee: HYBIO PHARMACEUTICAL CO., LTD.Inventors: Huixing Yuan, Guotao Li, Jian Liu, Yaping Ma, Jiancheng Yuan
-
Patent number: 10190145Abstract: The present disclosure describes methods and systems for improving the expression of a properly folded, biologically active protein of interest in a cell free synthesis system. The methods and systems use a bacterial cell free extract having an active oxidative phosphorylation system, and include an exogenous protein chaperone. The exogenous protein chaperone can be expressed by the bacteria used to prepare the cell free extract. The exogenous protein chaperone can be a protein disulfide isomerase and/or a peptidyl-prolyl cis-trans isomerase. The inventors discovered that the combination of a protein disulfide isomerase and a peptidyl-prolyl cis-trans isomerase produces a synergistic increase in the amount of properly folded, biologically active protein of interest.Type: GrantFiled: April 18, 2014Date of Patent: January 29, 2019Assignee: Sutro Biopharma, Inc.Inventors: Alice Yam, Dan Groff, Patrick Rivers, Christopher D. Thanos
-
Patent number: 10172407Abstract: A safety helmet that provides improved protection against injuries that can result from both linear and angular head acceleration is described. The helmet features an outer shell, an interface structure and a liner. The liner is a matrix structure formed from silkworm cocoons. Minimization of weight and sustainability, without compromising functionality, are also features of the helmet.Type: GrantFiled: June 10, 2016Date of Patent: January 8, 2019Assignee: New York UniversityInventors: Howard A. Riina, Fritz Vollrath
-
Patent number: 10138509Abstract: Methods of making a three-dimensional matrix of nucleic acids within a cell is provided.Type: GrantFiled: February 26, 2014Date of Patent: November 27, 2018Assignee: President and Fellows of Harvard CollegeInventors: George M. Church, Je-Hyuk Lee, Richard C. Terry, Evan R. Daugharthy
-
Patent number: 10106690Abstract: The present invention provides a surface-independent surface-modifying multifunctional biocoating and methods of application thereof. The method comprises contacting at least a portion of a substrate with an alkaline solution comprising a surface-modifying agent (SMA) such as dopamine so as to modify the substrate surface to include at least one reactive moiety. In another version of the invention, a secondary reactive moiety is applied to the SMA-treated substrate to yield a surface-modified substrate having a specific functionality.Type: GrantFiled: June 9, 2016Date of Patent: October 23, 2018Assignee: NORTHWESTERN UNIVERSITYInventors: Phillip B. Messersmith, Haeshin Lee
-
Patent number: 10087236Abstract: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.Type: GrantFiled: December 2, 2010Date of Patent: October 2, 2018Assignee: ACADEMIA SINICAInventors: Chi-Huey Wong, Chung-Yi Wu
-
Patent number: 9988413Abstract: The present invention discloses one pot process for the conversion of hemicellulose into C5 sugars using ionic liquids in water media.Type: GrantFiled: January 21, 2015Date of Patent: June 5, 2018Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Paresh Laxmikant Dhepe, Babasaheb Mansub Matsagar
-
Patent number: 9976133Abstract: Novel synthetic catalytic structures or “synzymes,” e.g., synthetic polypeptides, with catalytic properties are provided. It is believed that these synthetic catalytic structures mimic some of the precise conformational changes necessary for catalytic activities seen in enzymes. The catalytic properties of these synthetic catalytic structures or synzymes can be further improved by the application of controlled external forces, e.g., electric fields.Type: GrantFiled: June 20, 2013Date of Patent: May 22, 2018Assignee: The Regents of the University of CaliforniaInventors: Michael J. Heller, Tsukasa Takahashi, Michelle Lillian Cheung
-
Patent number: 9950075Abstract: The invention in some aspects provides compounds useful for targeting bacterial infections. In some embodiments, the compounds comprise a transferrin receptor ligand covalently linked to a bactericidal agent. In some embodiments, the bactericidal agent is a bactericidal peptide, such as a glycoside hydrolase (e.g., lysozyme).Type: GrantFiled: March 14, 2014Date of Patent: April 24, 2018Assignee: The University of MassachusettsInventors: Son N. Nguyen, Cedric E. Bobst, Igor A. Kaltashov
-
Patent number: 9926353Abstract: The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.Type: GrantFiled: July 16, 2012Date of Patent: March 27, 2018Assignee: New York UniversityInventors: Thomas M. Wisniewski, Fernando Goni
-
Patent number: 9908064Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.Type: GrantFiled: January 29, 2016Date of Patent: March 6, 2018Assignee: Leidos, Inc.Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
-
Patent number: 9782436Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.Type: GrantFiled: April 23, 2013Date of Patent: October 10, 2017Assignee: LifeCell CorporationInventor: Wenquan Sun
-
Patent number: 9757495Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally methods and related kits for the repair of articular tissue using the collagen material are provided.Type: GrantFiled: January 31, 2014Date of Patent: September 12, 2017Assignee: Children's Medical Center CorporationInventor: Martha M. Murray
-
Patent number: 9650433Abstract: Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.Type: GrantFiled: May 18, 2012Date of Patent: May 16, 2017Assignee: Momenta Pharmaceuticals, Inc.Inventors: Dorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
-
Patent number: 9617300Abstract: An excellent peptidyl peptidase-IV inhibitor and the like are provided. A peptide consisting of Val-Pro-X wherein X represents an amino acid residue (except for L-proline residue); the aforementioned X is preferably one selected from a basic amino acid residue, an aliphatic neutral amino acid residue, an amide group-carrying neutral amino acid residue, or an aromatic group-carrying neutral amino acid residue; the aforementioned X is preferably one selected from an alanine residue, a glutamine residue, a methionine residue, an asparagine residue, a glycine residue, a valine residue, a tyrosine residue, a serine residue, and a lysine residue; a dipeptidyl peptidase-IV inhibitor, a blood sugar rise suppressing agent, a vascular endothelial disorder suppressing agent, and an angiotensin converting enzyme inhibitor containing the aforementioned peptide as an active ingredient.Type: GrantFiled: February 21, 2013Date of Patent: April 11, 2017Assignee: MORINAGA MILK INDUSTRY CO., LTD.Inventors: Akio Yamada, Takuma Sakurai, Daisuke Ochi
-
Patent number: 9617299Abstract: A method of purifying a fusion protein, including: (1) adjusting the pH of an aqueous phase, containing a fusion protein which is a fusion of a protein having a self-assembly capability and a tamet protein, and which aqueous phase has a first pH, to a second pH, to obtain a remaining aqueous phase and a solid fraction containing an amount of the fusion protein; (2) separating the solid fraction from the remaining aqueous phase, to obtain a separated solid fraction; and (3) dissolving the separated solid fraction in a solution having a pH of 12 or lower but higher than the second pH by at least 0.1 pH units, wherein the protein having a self-assembly capability is a cell surface protein.Type: GrantFiled: April 21, 2016Date of Patent: April 11, 2017Assignee: AJINOMOTO CO., INC.Inventors: Takahiro Nonaka, Teruhisa Mannen, Noriko Tsurui
-
Patent number: 9611183Abstract: The present invention relates to production of inorganic fertilizers and biomass fiber suitable for thermal conversion processes. A method of producing biomass fiber for thermal conversion processes and inorganic mineral fertilizer from source biomass, includes mixing size reduced source biomass and a fluid under conditions favorable for extracting inorganic nutrients from the size reduced source biomass. A liquid extract phase and a solid phase are separated from the mixture. The liquid extract phase is then concentrated to obtain the inorganic fertilizer. The solid phase is dried to obtain biomass fiber for thermal conversion processes.Type: GrantFiled: November 6, 2013Date of Patent: April 4, 2017Assignee: BIOLINE CORPORATIONInventors: Mohamad Mogharab-Rahbari, Nicholas Ivan Ruzich
-
Patent number: 9597346Abstract: The present invention provides a method of reducing levels of at least one target protein in a cell. The cell is contacted with a first agent and a second agent. The first agent reduces synthesis of the target protein, e.g., by reducing levels of the mRNA of the target protein or inhibits translation of the mRNA. The second agent accelerates degradation of the target protein. The first agent may contact the cell before, after or simultaneously with the second agent. The first agent and the second agent may be in separate delivery vehicles, or in a single delivery vehicle. The first agent may be an RNAi (RNA interference) molecule, such as a small interfering RNA (siRNA), a small hairpin RNA (shRNA) or a microRNA (miRNA). The second agent may be a chimeric polypeptide containing a ubiquitin ligase polypeptide and a target protein interacting domain. The ubiquitin ligase polypeptide can be an E3 ubiquitin ligase, including, but not limited to, an SCF polypeptide, a HECT polypeptide and a UBR1 polypeptide.Type: GrantFiled: January 17, 2011Date of Patent: March 21, 2017Assignee: Cornell UniversityInventor: Pengbo Zhou
-
Patent number: 9540610Abstract: The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.Type: GrantFiled: April 28, 2011Date of Patent: January 10, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: Abdulhafez A. Selem, Lawrence A. Shimp, Hsiu Ying Sherry Wang
-
Patent number: 9528137Abstract: Cell-free protein synthesis systems and methods of using the same for producing in vitro protein materials in high yield are disclosed. The cell-free protein synthesis platform includes (a) a Saccharomyces cerevisiae cellular extract prepared from mid-exponential to late-exponential batch cultures in the range from about 6 OD600 to about 18 OD600 or fed-batch cultures harvested in mid-exponential to late-exponential phase; (b) a reaction buffer; and (c) a translation template or (c?) a transcription template from which a translation template can be prepared in situ with an RNA polymerase. A method of performing high-throughput protein synthesis in vitro is also provided that utilizes a combined transcription/translation reaction with the cell-free protein synthesis platform from Saccharomyces cerevisiae, an RNA polymerase and a transcription template prepared from a source DNA using an amplification procedure.Type: GrantFiled: March 14, 2014Date of Patent: December 27, 2016Assignee: Northwestern UniversityInventors: Michael C. Jewett, Charles E. Hodgman, Rui Gan
-
Patent number: 9526770Abstract: Disclosed herein, in certain instances, are methods of inhibiting osteoclast differentiation, bone resorption, bone formation, and bone remodeling in an individual in need thereof, comprising administering to the individual a composition comprising substantially fetal support tissue product including amniotic membrane and umbilical cord or an extract thereof, or a composition comprising substantially isolated HC-HA complex.Type: GrantFiled: April 27, 2012Date of Patent: December 27, 2016Assignee: TISSUETECH, INC.Inventors: Scheffer Tseng, Ek Kia Tan, Hua He
-
Patent number: 9511012Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.Type: GrantFiled: October 7, 2015Date of Patent: December 6, 2016Assignee: Silk Therapeutics, Inc.Inventors: Gregory H. Altman, Rebecca L. Horan, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
-
Patent number: 9499783Abstract: A sugar solution production apparatus includes a saccharification tank that obtains a saccharified solution containing a solid substance from a cellulose-containing biomass, a solid-liquid separator that separates the solid substance from the saccharified solution to obtain a sugar solution, an enzyme recovery solution tank that stores an enzyme recovery solution, a sugar solution extraction line that extracts the sugar solution from the solid-liquid separator, a warm water supply unit that supplies warm water to the solid-liquid separator, an enzyme recovery solution supply line that supplies the enzyme recovery solution from the enzyme recovery solution tank to the solid-liquid separator, an enzyme recovery solution recovery line that feeds the enzyme recovery solution containing the saccharifying enzyme recovered from the solid substance to the enzyme recovery solution tank, and an enzyme recovery solution return line that returns the enzyme recovery solution to the saccharification tank.Type: GrantFiled: September 13, 2012Date of Patent: November 22, 2016Assignee: Toray Industries, Inc.Inventors: Atsushi Minamino, Junpei Kishimoto, Hiroyuki Kurihara, Katsushige Yamada
-
Patent number: 9487771Abstract: The invention relates to new method of peptide hydrolysis, in particular of the cell walls of Gram-positive bacteria, wherein the active form of LytM or derivative thereof is contacted with a peptide substrate, preferably with the cell walls of Gram-positive bacteria, in an aqueous environment of conductivity lower than 10 mS/cm. The invention also relates to composition comprising active form of LytM or derivative thereof and new uses of active form of LytM or derivative thereof.Type: GrantFiled: October 17, 2013Date of Patent: November 8, 2016Assignee: MIEDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMORKOWEJInventors: Izabela Sabala, Matthias Bochtler
-
Patent number: 9464109Abstract: A method for the introduction of a labeling structure such as fluorescent molecules or a Raman tag to a compound is described. Imidazole functionalized resins or polymers are used to selectively immobilize phosphocompounds without protecting the carboxylic groups is described. Relying on the pKa difference between amines and hydrazides and carrying out the reaction in a slightly acidic buffer, all of the amines are protected by protonation while the hydrazides react with the phosphate imidazolide to form a phosphoramidate bond.Type: GrantFiled: September 30, 2014Date of Patent: October 11, 2016Assignee: INTEL CORPORATIONInventors: Handong Li, Narayan Sundararajan
-
Patent number: 9458446Abstract: The present invention relates to polypeptides having endopeptidase activity and to methods of producing and using the polypeptides. The invention also relates to methods of making a food protein hydrolysate using a trypsin-like endopeptidase derived from a bacterium.Type: GrantFiled: September 30, 2011Date of Patent: October 4, 2016Assignee: NOVOZYMES A/SInventors: Peter Rahbek Oestergaard, Carsten P. Sonksen, Tine Hoff, Gitte B. Lynglev
-
Patent number: 9410170Abstract: Improved methods are provided in vitro synthesis of biological molecules, providing for improved yields, lowered costs, and enhanced utility. Improved yield and lowered cost is obtained by the use of a phosphate free energy source in the presence of exogenous phosphate, and optionally in the absence of exogenous nucleoside triphosphates.Type: GrantFiled: November 18, 2004Date of Patent: August 9, 2016Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Kara Calhoun, Michael Christopher Jewett, James Robert Swartz